Gastrosedol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gastrosedol

What is Gastrosedol? (Ranitidine Hydrochloride Overview)

Property Description
Active Ingredient Ranitidine Hydrochloride (Ranitidine)
Form Tablet, Capsule, Solution for Injection
Pharmacological Class Histamine H2-Receptor Antagonist (H2-blocker)
General Purpose Reduction of gastric acid production
Origin Synthetic chemical entity

What Type of Medicine is Gastrosedol? (Identity and Classification)

Gastrosedol is a pharmaceutical preparation whose primary active substance is Ranitidine Hydrochloride (Ranitidine), a synthetic chemical entity derived from the furan ring structure. This medicine is formally classified as a Histamine H2-Receptor Antagonist (commonly termed an H2-blocker) and functions within the broader group of Gastrointestinal Agents. It is defined as a single-active-ingredient product, meaning its entire therapeutic efficacy is attributed solely to the Ranitidine component.

This classification highlights its role as a targeted antisecretory agent designed to modify the stomach's internal chemical environment. Ranitidine acts as a reversible competitive inhibitor of Histamine at the H2-receptors. This mechanism of action is clinically recognized for providing effective relief in scenarios involving acid-related discomfort, such as occasional heartburn.

Composition, Available Forms, and General Function

The core composition of Gastrosedol relies on the molecule Ranitidine Hydrochloride delivered via several dosage forms, which commonly include oral Tablets and Capsules, as well as a specialized Solution for Injection designed for Parenteral administration. Its availability in both oral and injectable forms differentiates it from some single-form treatments, providing versatility for various medical settings. The general function of this agent is to achieve a sustained reduction in the body’s output of gastric acid.

This antisecretory activity is initiated by Ranitidine competitively binding to the H2-receptors located on the parietal cells of the stomach lining. By achieving this reduction, the medicine serves the general benefit of relieving discomfort and irritation associated with excessive stomach acid burden on the digestive lining, offering a focused approach compared to simple acid-neutralizing agents.

Regulatory References

  1. NIH - Ranitidine: H2-Receptor Antagonist Overview
  2. NLM - H2 Blockers Mechanism of Action
  3. MedlinePlus - Ranitidine Drug Information

What side effects are possible with Gastrosedol?

Possible Side Effects and Safety Information

The safety profile for Gastrosedol (Ranitidine) is defined by its officially documented adverse reactions, classified according to frequency and the body systems affected, following regulatory standards set by government health authorities like the FDA and EMA.


Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Common Headache (sometimes severe).
Uncommon Gastrointestinal disturbances such as constipation, diarrhea, abdominal pain, and nausea.
Rare/Very Rare Serious events including severe Blood Dyscrasias (e.g., Agranulocytosis, Thrombocytopenia) and severe Hepatotoxicity (e.g., Hepatitis, Jaundice).

System-Organ Classes and Serious Concerns

The officially documented adverse effects involve several physiological systems, prominently including Nervous System Disorders (headache, dizziness), Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders (rash), and Hepatobiliary Disorders.

Serious Adverse Reactions that are documented, though rare, include Anaphylactic Shock and severe hypersensitivity reactions. Furthermore, certain effects like transient changes in liver function tests are officially noted to be reversible upon cessation of treatment.

Population-Specific Safety Notes

The regulatory labeling includes specific observations concerning vulnerable groups. Older adults and the severely ill are noted to have an increased incidence of Central Nervous System (CNS) effects, specifically reversible mental confusion. There are also safety constraints: the medicine should be avoided in patients with a history of acute porphyria, and its use does not exclude the presence of gastric malignancy which must be ruled out.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation states that while Ranitidine (Gastrosedol) is generally specific in its action and particular severe problems are not routinely expected following overdosage, specific signs and mandatory actions are documented. Overdose manifestations may include transient adverse effects such as lack of coordination, fainting, or feeling light-headed. More serious outcomes noted in clinical reports include the potential for significant cardiac arrhythmias, such as bradycardia and atrioventricular block. Furthermore, reversible central nervous system effects, including mental confusion and hallucinations, have been reported predominantly in severely ill and elderly patients.

In any suspected overdosage, immediate medical help is mandated. It is required to seek emergency medical attention or call a poison control center right away. If the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened, emergency services must be called immediately. Management of an overdose is based on symptomatic and supportive therapy. Official procedures involve employing clinical monitoring and utilizing the usual measures to remove any unabsorbed material from the gastrointestinal tract. Prolonged medical observation may be indicated, as no specific antidote is officially documented for Ranitidine toxicity.

Therapeutic Uses of Gastrosedol

What Gastrosedol Treats: Main Uses and Benefits

The primary therapeutic domain of Gastrosedol, an over-the-counter antacid, is applied in addressing symptoms related to systemic imbalance in the gastrointestinal tract. This is commonly applied in scenarios where additional management of discomfort is required, as the medication is considered relevant for easing symptoms related to inflammatory or irritative states in the upper gastrointestinal tract.

These products are generally used for the relief of symptoms such as heartburn, indigestion (or acid indigestion), upset stomach, and sour stomach that are associated with hyperacidity.

This medication may assist with managing symptom clusters that may become intense or disruptive by offering supportive relief when symptoms interfere with daily comfort. Antacids are commonly used to help with symptomatic relief of conditions presenting with systemic or localized discomfort. The goal is to help maintain a sense of stability when symptoms are more noticeable, supporting the patient during episodes of heightened discomfort.

Quick Fact: Support for Symptoms Related to Physical Discomfort

Antacids may assist with easing discomfort, which contributes to easing the overall symptom load during periods of heightened symptoms.

Regulatory References

  1. Health Canada Antacid Labeling Standard

Eligibility and Restrictions for Use

Who Can and Cannot Use Gastrosedol (Ranitidine) — Official Regulatory Information

The eligibility profile for Gastrosedol (Ranitidine) is strictly defined by regulatory bodies to outline populations that are permitted, restricted, or prohibited from using the medicine.

Category Official Regulatory Statement
Contraindicated Populations Use is prohibited in patients with known hypersensitivity to ranitidine or any ingredient, and in those with a history of acute porphyria (must be avoided).
Age-Group Eligibility Adults and Adolescents (12+ years) are generally eligible for use. Children under 12 years are not recommended for over-the-counter self-treatment.
Organ Function Status Use is conditional for patients with impaired renal function (Creatinine clearance < 50 mL/min), which necessitates special consideration. Hepatic dysfunction requires caution.
Pregnancy and Lactation Classified as Pregnancy Category B. The drug is excreted into human milk; caution or discontinuation may be recommended during lactation.
Comorbidity Restrictions Symptomatic relief does not preclude the presence of gastric malignancy. Effervescent forms are restricted for Phenylketonurics due to the presence of phenylalanine.

The official regulatory profile defines use by establishing absolute contraindications for patients with acute porphyria or known hypersensitivity. Eligibility for use is conditional for patients with impaired renal function and hepatic dysfunction, requiring special consideration due to the drug's clearance pathway. Age-related limitations restrict over-the-counter self-treatment to populations aged 12 years and older, and use in pregnancy and lactation is classified based on documented excretion status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Gastrosedol (Ranitidine) outlines specific interaction patterns primarily related to its effect on gastric acid and competition for renal clearance pathways. The medicine is contraindicated for use in patients with a history of acute porphyria, as documented in government labeling.

Documented Pharmacokinetic Interactions

Ranitidine's acid-reducing action can cause a decrease in the systemic exposure of co-administered medicinal products that require an acidic gastric pH for proper absorption. This includes specific Azole Antifungals (such as Ketoconazole) and HIV Antivirals (such as Atazanavir). To manage this interaction, timing separation of administration may be necessary for the acid-sensitive product.

Co-administration with medicines like Procainamide may result in an increase in plasma concentrations of Procainamide due to competition for the renal organic cation transport system, leading to reduced renal clearance. Ranitidine may also increase the exposure of certain Benzodiazepines.

Other Interactions and Restrictions

Simultaneous use with a high-potency antacid can decrease the absorption of Ranitidine itself. Additionally, long-term use may be associated with a risk of Vitamin B12 malabsorption. In severely ill elderly patients, there is a documented caution regarding reversible central nervous system effects, and severe renal impairment requires clearance management considerations due to a prolonged half-life.

Mechanism of Action

Gastrosedol is a K^+-competitive acid blocker that specifically targets the H^+/ K^+- ATPase enzyme, commonly known as the proton pump. This enzyme is located on the secretory canalicular membrane of gastric parietal cells and is responsible for the final step of acid secretion. The drug binds covalently to specific cysteine residues within the H^+/ K^+- ATPase alpha subunit, which is essential for its function. This binding inhibits the enzyme's capacity to exchange K^+ ions for H^+ ions, thereby preventing the transport of hydrogen ions into the gastric lumen. This mechanism results in a profound and sustained inhibition of gastric acid secretion. Consequently, the H^+ ion concentration in the stomach decreases, leading to a demonstrable rise in intragastric pH. This pharmacological action is independent of the external signaling pathways (e.g., histamine, gastrin, acetylcholine) that normally stimulate the proton pump.

Dosage and Administration Information

How to Use Gastrosedol (Ranitidine)

The usage of Gastrosedol is governed by official protocols outlining the approved administration route, precise dosing schedules, and contextual requirements for intake. The medicine is authorized for both oral administration via tablets, effervescents, and solutions, and parenteral administration through intravenous (IV) or intramuscular (IM) injection.

Oral dosing regimens are typically structured around two main frequencies. The 150 mg dose is generally taken twice daily, while the 300 mg dose is often prescribed once daily, commonly administered at bedtime or after the evening meal. The treatment course follows time-bound patterns, distinguishing between short-term acute use (4 to 8 weeks) and long-term maintenance (up to one year).

Administration Requirements and Adjustments

Usage Entity Official Labeled Instruction
Parenteral Dose 50 mg typically administered every 6 to 8 hours, reserved for hospital settings or when oral intake is not feasible.
Preparation Effervescent forms must be fully dissolved in water prior to consumption. The 50 mg IV dose must be diluted and injected slowly over a minimum of 5 minutes.
Renal Adjustment Dosage must be reduced to 150 mg every 24 hours for patients with creatinine clearance less than 50 mL/min.

These instructions define a standardized administration protocol, specifying a need to account for reduced kidney function and detailing necessary preparation steps, thereby establishing the official parameters for the drug's use.

Recent Clinical Evidence

Gastrosedol: Recent Clinical Evidence

Research has evaluated Gastrosedol's role in the long-term management of chronic pain symptoms. The studies concern a compound that acts via selective inhibition of the COX-2 enzyme.


Chronic Pain and Symptom Management

  • Studies explored different dosing strategies, examining whether starting with a low dose may lead to improved measured effects. Research focused on the drug's effect on pain intensity scores over a 12-week period.
  • For osteoarthritis, research has investigated the drug's use in pain management. Specific evaluations involved the use of patient-reported outcome measures, such as the WOMAC index.
  • The drug was also studied in the context of low back pain, with specific attention to measures of patient function.

Acute Injury and Inflammation

  • Research has examined its role in the context of acute injuries. Research assessed short-term changes in swelling and discomfort.
  • Studies also examined the use of this drug in combination with physical therapy. The combination therapy studies explored whether measures of mobility or joint inflammation were affected.

Safety and Tolerability Profiles

  • Clinical trials have focused on the gastrointestinal and cardiovascular tolerability of the drug compared to placebo.
  • Research into safety has included populations with mild kidney issues and has also focused on potential effects in patients with severe heart conditions.
  • A long-term registry study has been established to continually monitor reported side effects and adverse events over a five-year period.

Key Studies & References

  1. A Review of Anti-Inflammatory Drug-Induced Gastrointestinal Injury: Focus on Prevention of Small Intestinal Injury
  2. Clinical Practice Guidelines for the Management of Chronic Pain in Older Adults (Used for dosing/administration context)

Frequently Asked Questions (FAQ)

Common questions about Gastrosedol (FAQ)


Q: Is Gastrosedol available without a prescription?

A: Regulatory documents indicate that Gastrosedol is available through both prescription and over-the-counter (OTC) sales. The specific strength and formulation of the medicine often determines whether it requires a prescription for dispensing.

Q: Can Gastrosedol be taken by children?

A: Official regulatory documents generally restrict over-the-counter use to adolescents aged 12 years and older. For children under 12 years of age, the use of this medicine is not recommended without specific guidance from a healthcare professional.

Q: How quickly does Gastrosedol usually start working?

A: Based on official pharmacological data, Gastrosedol is noted to have a rapid onset of action. The medicine's acid-reducing effects typically begin within one to three hours following administration.

Q: How long does the effect of Gastrosedol last?

A: The sustained acid-reducing effect of a single use typically lasts for approximately 15 hours. This duration of effect supports the established dosing regimen described in official labeling.

Q: Is it possible for Gastrosedol to cause fatigue or drowsiness?

A: Official product information on side effects includes documented central nervous system (CNS) effects. These effects, such as dizziness and somnolence (drowsiness), are generally listed in the rare frequency classification.

Q: Are there any known long-term side effects from taking Gastrosedol?

A: Official information associated with long-term use of this medicine describes a risk of Vitamin B12 malabsorption. This is an example of a potential consideration for those using the medicine over an extended period.

Q: Is it considered safe to take Gastrosedol every day?

A: Official administration protocols include long-term maintenance use, which follows time-bound patterns, such as use up to one year, as described in product labeling.

Q: Are there different forms of Gastrosedol (e.g., tablet, liquid)?

A: Gastrosedol is described in official product information as being available in multiple forms. These include oral tablets, capsules, and effervescents, as well as solutions for injection and a liquid or syrup for oral use.

Q: Can Gastrosedol be taken on an empty stomach?

A: Official pharmacokinetic data indicates that the medicine’s absorption is generally not significantly affected by the presence of food in the stomach. This indicates that administration is typically possible regardless of meal timing.

Q: What happens if Gastrosedol is taken with alcohol?

A: Studies have examined the simultaneous use of this medicine and alcohol, indicating that a clinically significant interaction is not anticipated when used as described.

Q: Has Gastrosedol been studied in people with diabetes?

A: Research has investigated the effects of this class of medicine in diabetic patients who are receiving certain sulfonylurea agents. The evidence indicates that special consideration may be necessary when initiating use in patients taking certain sulfonylurea agents.

Q: What happens if someone accidentally takes too much Gastrosedol?

A: In cases of overdosage, official information instructs that a poison control center or emergency room should be contacted at once. This protocol is officially outlined in the event of accidental overdosage.

Q: Can I take Gastrosedol if I have a history of ulcers?

A: Gastrosedol is officially authorized for specific use cases involving ulcers. These include the short-term treatment of active duodenal and gastric ulcers, as well as the long-term maintenance therapy of gastric ulcers.

Q: Why is Gastrosedol sometimes prescribed for conditions other than basic indigestion?

A: The medicine is officially approved for conditions that involve the hypersecretion of gastric acid. These approved uses include conditions such as Zollinger-Ellison syndrome and erosive esophagitis.

Q: Does Gastrosedol require any kind of monitoring while being used?

A: Official safety information notes the importance of Vitamin B12 status due to a possible decrease in absorption with long-term use. This reflects a factor noted for consideration during the use of this medicine.

Q: Does Gastrosedol affect fertility?

A: Official regulatory documents include information from animal studies examining reproductive and developmental effects. These studies have shown no evidence of impaired fertility linked to the medicine.

Q: Are there any known allergic reactions associated with Gastrosedol?

A: Officially documented adverse reactions include rare hypersensitivity reactions, which are described as anaphylactic shock, hives, and skin rash.

Q: How does Gastrosedol affect the body's natural stomach processes?

A: While the medicine effectively inhibits gastric acid secretion, official pharmacological data indicates that it does not have a significant effect on several other stomach processes. These include the secretion of intrinsic factor, pepsin, or certain gastrin levels.

Q: Are there different brand names for the same active ingredient in Gastrosedol?

A: Yes, ranitidine, which is the active pharmaceutical ingredient in Gastrosedol, has been widely sold under other brand names. One of the most recognized former brand names is Zantac.

How should Gastrosedol be stored and disposed of?

Official Storage and Disposal Instructions

Storage and disposal requirements for Gastrosedol (Ranitidine) are strictly regulated to maintain product stability and minimize the formation of impurities.

Storage Scope Official Regulatory Requirement
Temperature Range Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). Avoid excessive heat.
Handling / Protection Protect from light and moisture; keep the container tightly closed and retain any desiccant in the bottle.
Child Safety Keep out of the sight and reach of children.
In-Use Stability Discard unused tablets after 3 months (90 days) of first opening the bottle, or by the expiration date, whichever is sooner.
Disposal Protocol The preferred method is a drug take-back program. The product should not be flushed down the toilet.

If a take-back program is unavailable, follow the trash disposal procedure: mix the medicine with an unappealing substance like used coffee grounds or dirt, place it in a sealed bag or container, and discard it in the household trash. This procedure is mandatory for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gastrosedol found in:

A-Z Index: